FDA Approves Novo Nordisk Awiqli as First Once Weekly Insulin for Children With Type 2 Diabetes

Novo Nordisk won US clearance on October 23, 2026 for Awiqli, or insulin icodec-abae, as a once weekly basal insulin for children aged 10 and older with type 2 diabetes. The Food and Drug Administration approval makes the 700 units/mL injection the first once weekly basal insulin available for pediatric type 2 diabetes in the United States. The product is already familiar to adult patients, but the pediatric label turns seven basal injections a week into one.

Type 2 diabetes in young people is not a small or static problem. Novo Nordisk cited a modeling study projecting nearly 84,000 people aged 19 or younger in the United States with type 2 diabetes by 2050. Eda Cengiz, MD, MHS, professor of pediatrics at the University of California, San Francisco, said in Novo's announcement that children with type 2 diabetes face an aggressive disease trajectory and that daily basal injections have been a mainstay of pediatric care for more than 20 years.

Awiqli is not a new chemical entity for adults. The FDA approved the adult type 2 diabetes indication in March 2026, making it the first once weekly basal insulin for adults with type 2 diabetes, Healio reported. The pediatric approval builds on the adult evidence package and a single dose pharmacokinetic study in patients aged 10 to under 18 with type 2 diabetes. Novo said results from that study plus data from the ONWARDS clinical trials supported the pediatric indication.

The approval lands in a competitive but uneven market. Eli Lilly's insulin efsitora alfa-gobe, sold as Onswik, was approved about one month earlier as the second once weekly basal insulin for adults, according to Healio. Onswik is not currently approved for children, leaving Novo with the only pediatric weekly basal insulin in the US market. Pediatric type 2 diabetes has few treatment options, and the injection burden is one of the practical limits that clinicians and families discuss.

Key Facts

PR Newswire reported on October 23, 2026 that Novo Nordisk announced FDA approval of Awiqli injection 700 units/mL as an adjunct to diet and exercise to improve glycemic control in children aged 10 years and older with type 2 diabetes. The label specifies once weekly subcutaneous injection on the same day each week using the FlexTouch pen. Basal injections fall from seven per week to one, or from about 365 a year to 52, as Medical Daily reported on August 18, 2026.

Healio reported on October 23, 2026 that the pediatric expansion rests on evidence from adult studies and a single dose pharmacokinetic study in children aged 10 to 17 with type 2 diabetes. Novo said efficacy and safety data from the ONWARDS clinical trials supported the approval. The adult approval had arrived in March 2026, when the FDA cleared the product as the first once weekly basal insulin for adults with type 2 diabetes.

Managed Healthcare Executive reported on August 11, 2026 that Awiqli launched in the US with a list price of $99 per package, a single multi-dose FlexTouch pen. Eligible commercially insured or Medicare patients can pay as little as $35 a month through NovoCare savings programs, while uninsured patients pay $55 a month. Patients whose plans use copay accumulator or maximizer arrangements are excluded from the savings cards. Novo said the product would be available at more than 70,000 US pharmacies.

The adult evidence base is the ONWARDS phase 3a program, which enrolled about 2,680 adults with uncontrolled type 2 diabetes across four randomized trials. Managed Healthcare Executive reported on August 11, 2026 that the trials showed non-inferiority to once daily insulin degludec or insulin glargine plus an oral antidiabetic drug on mean change in HbA1c. The pediatric label does not repeat those adult trials in children. Instead, the FDA relied on adequate and well controlled studies in adults plus the single dose pharmacokinetic study in pediatric patients.

The safety profile includes hypoglycemia, serious allergic reactions, injection site reactions, lipodystrophy, itching, rash, swelling of hands and feet, and weight gain. Novo states that it is not known whether Awiqli is safe and effective in children younger than 10. The product is approved in the US, the EU and 18 additional countries. For US pediatric use, the approval is limited to type 2 diabetes, not type 1 diabetes.

Analysis

The approval is best read as a targeted reduction in treatment burden rather than a redefinition of pediatric diabetes care. Awiqli does not replace metformin, lifestyle support or the broader need for glucose control. It changes the delivery schedule for children who already need basal insulin. Reuters reported on April 23, 2026 that treatment options for young patients remain limited, with doctors typically relying on metformin or insulin for pediatric type 2 diabetes. A once weekly basal option fits inside that narrow set of choices, but it does not expand the set by itself.

What this really means is that convenience has become a regulatory and clinical selling point in a field where adherence is not an abstract concern. A child who needs a daily basal injection depends on a family routine, school schedules and caregiver availability. A weekly injection on the same day each week can reduce those handoffs from 365 to 52 a year. The trade-off is not invisible. Medical Daily reported on August 18, 2026 that because a once weekly insulin stays in the body far longer than a daily one, a dosing error takes longer to correct. European regulators required educational materials on avoiding errors and mix ups when switching from a daily long acting insulin, and the US label keeps the same day each week instruction.

The bigger picture here is that Novo is building a pediatric franchise around an adult product with an established manufacturing and pharmacy footprint. Managed Healthcare Executive reported on August 11, 2026 that the adult label was limited to type 2 diabetes after an FDA advisory committee concluded the data were not sufficient to establish a positive benefit risk profile in type 1 diabetes. Medical Daily reported on August 18, 2026 that the FDA issued a complete response letter in 2024 to an earlier application covering both major diabetes types, citing manufacturing questions and concerns about hypoglycemia risk in type 1 diabetes. An advisory panel voted against type 1 use while raising no comparable safety concern for type 2. The pediatric approval extends the type 2 label to a younger age group using adult evidence and a pediatric pharmacokinetic study.

The competitive contrast with Eli Lilly is sharper than a simple first mover story. Healio reported on October 23, 2026 that Onswik was approved about one month before Awiqli's pediatric expansion as the second once weekly basal insulin for adults and is not currently approved for children. Novo therefore has a pediatric label that Lilly does not have, at least for now. But the adult market is already contested, and the pediatric niche is small relative to the adult type 2 population. The approval gives Novo a differentiated claim, not a mass market monopoly.

Why It Matters

The pediatric approval matters because the numbers behind type 2 diabetes are large and the pediatric slice is growing. Managed Healthcare Executive reported on August 11, 2026 that about 40 million Americans have diabetes and roughly 90% to 95% of them have type 2 diabetes, according to the CDC. Medical Daily reported on August 18, 2026 that more than 36 million people in the United States have type 2 diabetes, with about 22% of them, roughly 8 million people, requiring daily insulin injections to control blood glucose, citing figures reported by the Washington Post. Those adult figures do not describe the pediatric population, but they show the scale of the insulin dependent segment that a weekly option is trying to reach.

For families, the practical difference is a year of fewer injections and fewer opportunities for missed doses. For clinicians, the harder part is switching. Medical Daily reported on August 18, 2026 that switching requires converting the total weekly insulin requirement rather than making a simple substitution, and that the first dose may be handled differently from later ones. That is why the label, the pen and the education materials matter as much as the once weekly schedule. A convenience product that is used incorrectly is not convenient.

For Novo, the approval also arrives while the company is pursuing a broader pediatric diabetes strategy. Reuters reported on April 23, 2026 that Novo's oral GLP-1 drug significantly lowered blood sugar in children and adolescents with type 2 diabetes in a late stage trial, testing 132 patients aged 10 to 17 over 26 weeks. Patients taking the drug lowered average blood sugar by 0.83 percentage points more than those given placebo, a difference the company said was statistically significant. Novo said it would seek regulatory approval for its semaglutide pill and expected to file for label expansions for the Ozempic pill and Rybelsus in the US and EU in the second half of 2026.

Next Up

The next test is access. Novo says Awiqli is stocked at more than 70,000 US pharmacies, but formulary placement is decided plan by plan, and the savings card excludes patients whose plans use copay accumulator or maximizer arrangements. Pediatric use will depend on whether clinicians convert weekly insulin requirements correctly and whether families can navigate prior authorization and cost sharing. The label does not answer the question for children younger than 10, and Novo states that safety and effectiveness in that group are not known.

The competitive and clinical agenda is already moving. Healio reported on October 23, 2026 that Onswik is not approved for children, leaving Novo alone in the US pediatric weekly basal insulin market for now. Reuters reported on April 23, 2026 that Novo expected to file for pediatric label expansions for its semaglutide pill products in the US and EU in the second half of 2026. If those filings advance, Novo could end up with both a weekly insulin and an oral GLP-1 option for young patients with type 2 diabetes. The FDA approval of Awiqli is one step in that broader push, not the end of it.